AGL 38.00 No Change ▼ 0.00 (0%)
AIRLINK 210.00 Decreased By ▼ -0.38 (-0.18%)
BOP 9.40 Decreased By ▼ -0.08 (-0.84%)
CNERGY 6.28 Decreased By ▼ -0.20 (-3.09%)
DCL 8.66 Decreased By ▼ -0.30 (-3.35%)
DFML 42.21 Increased By ▲ 3.84 (10.01%)
DGKC 94.00 Decreased By ▼ -2.92 (-3.01%)
FCCL 34.83 Decreased By ▼ -1.57 (-4.31%)
FFBL 88.94 No Change ▼ 0.00 (0%)
FFL 15.97 Increased By ▲ 1.02 (6.82%)
HUBC 126.49 Decreased By ▼ -4.20 (-3.21%)
HUMNL 13.25 Decreased By ▼ -0.04 (-0.3%)
KEL 5.29 Decreased By ▼ -0.21 (-3.82%)
KOSM 6.94 Increased By ▲ 0.01 (0.14%)
MLCF 42.99 Decreased By ▼ -1.79 (-4%)
NBP 58.99 Decreased By ▼ -0.08 (-0.14%)
OGDC 218.50 Decreased By ▼ -11.63 (-5.05%)
PAEL 38.59 Decreased By ▼ -0.70 (-1.78%)
PIBTL 8.18 Decreased By ▼ -0.13 (-1.56%)
PPL 189.50 Decreased By ▼ -10.85 (-5.42%)
PRL 37.75 Decreased By ▼ -1.13 (-2.91%)
PTC 26.20 Decreased By ▼ -0.68 (-2.53%)
SEARL 101.90 Decreased By ▼ -1.73 (-1.67%)
TELE 8.32 Decreased By ▼ -0.13 (-1.54%)
TOMCL 34.69 Decreased By ▼ -0.56 (-1.59%)
TPLP 12.75 Decreased By ▼ -0.77 (-5.7%)
TREET 25.20 Increased By ▲ 0.19 (0.76%)
TRG 69.22 Increased By ▲ 5.10 (7.95%)
UNITY 33.23 Decreased By ▼ -1.29 (-3.74%)
WTL 1.70 Decreased By ▼ -0.08 (-4.49%)
BR100 11,851 Decreased By -245 (-2.03%)
BR30 36,710 Decreased By -1005.2 (-2.67%)
KSE100 109,863 Decreased By -2551.5 (-2.27%)
KSE30 34,587 Decreased By -920.9 (-2.59%)

NEW YORK: A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.

The two pharmaceutical giants said they intend to appeal the decision, which concluded that the companies engaged in unfair and deceptive business practices.

The state of Hawaii alleged the companies misled consumers about the benefit of using the drug, particularly for people of East Asian ancestry.

The drug makers “intend to appeal the trial court’s decision and we are confident in our success on appeal,” the companies said.

The state pointed to results showing the treatment did not work well for some patients of Asian or Pacific-island descent who could not properly metabolize the drug, according to the reports.

But the two companies disagreed, saying, “Leading cardiologists have examined the scientific evidence and continue to recommend Plavix as the standard of care for all its indications regardless of race or ethnicity.

Comments

Comments are closed.